Allergic rhinitis

Global Skin Allergy Testing Market Expected to Reach $771.5 Million by 2028

Retrieved on: 
Donnerstag, Mai 9, 2024
Education, Dermatitis, Asthma, Hospital, Allergy, Allergic conjunctivitis, Drug allergy, Allergen, Automation, Food, Incidence, Diagnosis, BCC, Health, Allergic rhinitis, Atopic dermatitis, Skin, Growth, Prevalence

BOSTON, May 9, 2024 /PRNewswire/ -- "According to the latest BCC Research study, the demand for Global Skin Allergy Testing Market is expected to grow from $560 million in 2023 and is projected to reach $771.5 million by the end of 2028, at a compound annual growth rate (CAGR) of 6.6% during the forecast period."

Key Points: 
  • The report provides an in-depth overview of the global skin allergy testing market and provides comprehensive insights into its dynamics and future trajectory till 2028.
  • The skin prick test segment largely dominates the skin allergy testing market as it is widely used as the primary method of allergy testing.
  • Furthermore, the integration of automation in skin prick testing, fueled by technological advancements, may revolutionize the skin allergy testing landscape and is expected to drive significant market development soon.
  • These joint efforts are helping to expand the global skin allergy testing market.

Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Asthma, CFO, Cancer, Inflammation, Eosinophilic bronchitis, Research, Culture, Food, Patient, Drug development, Allergic rhinitis, Atopic dermatitis, Therapy, Growth, Pharmaceutical industry

Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief Executive Officer (CEO).

Key Points: 
  • Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief Executive Officer (CEO).
  • Grégoire Chevalier brings over 10 years of research and drug development experience to Atopia Therapeutics.
  • Under Grégoire Chevalier’s leadership, Atopia Therapeutics will continue the development of novel treatments that address the underlying mechanisms of atopic diseases.
  • “As we embark on our next phase of growth and expansion, we are thrilled to welcome Grégoire Chevalier as the new CEO of Atopia Therapeutics,” said Board Member Jacques Billy, CFO of Atopia Therapeutics.

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Retrieved on: 
Donnerstag, Mai 2, 2024
TSX, Doctor of Philosophy, Esophagus, MPH, Immunoglobulin E, Allergic rhinitis, Asthma, Eosinophilic esophagitis, Pharmaceutical industry

VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program.

Key Points: 
  • VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program.
  • The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano and Dr. Roos Pouw.
  • The Clinical Advisory Board will work closely with Eupraxia as it continues its development of EP-104GI for eosinophilic esophagitis ("EoE"), which is currently in a Phase 1b/2a clinical trial.
  • "The formation of our Gastrointestinal Clinical Advisory Board comes at an exciting time for our Company, as we continue to generate clinical evidence in support of EP-104GI for the treatment of eosinophilic esophagitis," said Mark Kowalski, MD, PhD, Chief Medical Officer of Eupraxia.

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

Retrieved on: 
Donnerstag, Mai 2, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Hospitals, Other Health, Public, Society, Risk, GINA, MD, Doctor of Philosophy, Global Initiative for Asthma, Allergen, AIT, Patient, Allergic rhinitis, Pulmonology, Asthma, Quality of life, Pharmaceutical industry

The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.

Key Points: 
  • The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.
  • “Exploring the impact of allergen immunotherapy on asthma onset and progression is crucial, and we're committed to filling those gaps.
  • Through this real-world EfficAPSI study, Stallergenes Greer is honoured to contribute valuable scientific evidence and insights to allergy treatment.
  • By demonstrating the benefit on the onset and worsening of asthma, Stallergenes Greer SLIT-liquid treatments confirm their impact in terms of public health.

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Retrieved on: 
Mittwoch, April 10, 2024
FDA, Drug discovery, Synovitis, Cell, Research, Vaccine, IND, Nanoparticle, Allergic rhinitis, DNMT3B, Dicarboxylic acid, Inflammation, Hearing loss, Osteoarthritis, Vertigo, RNA, Myocardial infarction, Patent, CHF, Messenger, Betahistine, Therapy, Semaphore, AVS, Dizziness, AAV, Tinnitus, Heqet, Rhinitis, Central nervous system, Clinical trial, Small RNA, Sale, Cancer, EDT, Liver, Patient, Rheumatoid arthritis, Histamine, Regeneration

HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.

Key Points: 
  • "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
  • "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
  • Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
  • Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.

Global Skin Allergy Testing Market Report 2024: Revenue Data for 2020-2022, Estimated Figures for 2023, and Forecasts for 2028 - ResearchAndMarkets.com

Retrieved on: 
Freitag, April 26, 2024
Health, Other Health, Asthma, Allergic rhinitis, Allergic conjunctivitis, Drug allergy, Anaphylaxis, Hospital, Cosmetics

This report provides detailed information about the global skin allergy testing market.

Key Points: 
  • This report provides detailed information about the global skin allergy testing market.
  • It also analyzes the size of the skin allergy testing market based on test types, applications and end users.
  • Based on applications, the skin allergy testing market is segmented into allergic rhinitis, allergic asthma, drug allergy, allergic conjunctivitis, anaphylaxis and others.
  • Analysis of global market trends, featuring revenue data for 2020-2022, estimated figures for 2023, and forecasts for 2028.

Aptar Reports First Quarter 2024 Results

Retrieved on: 
Donnerstag, April 25, 2024
Packaging, Pharmaceutical, Health, Manufacturing, Decongestant, Central Time, Investment, Emergency medicine, ERP, Therapy, Translation, Acquisition, AptarGroup, Central nervous system, Allergic rhinitis, Asthma, Growth, Beauty, Interest

Aptar Pharma had an increase in reported sales of 14% and cores sales of 13% over the prior year quarter.

Key Points: 
  • Aptar Pharma had an increase in reported sales of 14% and cores sales of 13% over the prior year quarter.
  • Sales improved for the Injectables division, rebounding from the Enterprise Resource Planning (ERP) implementation headwind that impacted the first quarter results of 2023.
  • Aptar Beauty’s reported sales were flat compared to the prior year quarter, and with currency effects core sales were down slightly.
  • There will be a conference call held on Friday, April 26, 2024 at 8:00 a.m. Central Time to discuss the company’s first quarter results for 2024.

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Retrieved on: 
Sonntag, Februar 25, 2024
Allergy, Ophthalmology, AAAAI, Omalizumab, Upper respiratory tract infection, Dermatology, Allergic rhinitis, Season, Hematology, Rhinitis, Immunology, Patient, Autoimmunity, Clinical trial, PPP, SOC, Asthma, Insurance, American Academy, Pharmaceutical industry

The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.

Key Points: 
  • The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.
  • This Phase II study shows that 100mg LP-003 significantly improved nasal symptoms (TNSS score) of uncontrolled seasonal allergic rhinitis patients despite SoC treatment.
  • We are honored to unveiled the exciting Phase II results of LP-003, the first registrational clinical trial of anti-IgE antibody for AR conducted in China."
  • As Longbio Pharma charts its course forward, the successful Phase II study of LP-003 in allergic rhinitis represents a pivotal milestone in advancing the treatment landscape for allergic diseases.

The Development of Allergic Disease Not Associated with Prenatal PM2.5 Air Pollution Exposure

Retrieved on: 
Freitag, Februar 16, 2024
Wheeze, Incidence, Air pollution, AAAAI, Research, Food allergy, Multimedia, Asthma, Allergic rhinitis, Pregnancy, University, Health, Particulates, Patient, Journal, Dermatitis, American Academy, Cochineal

MILWAUKEE, Feb. 16, 2024 /PRNewswire-PRWeb/ -- No significant association was found between ambient particulate matter (PM2.5) exposure and incidences of asthma, allergic rhinitis or eczema according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting in Washington, DC this month.

Key Points: 
  • In settings of low overall air pollution levels, differences in the development of allergic disease by race were not significant in new birth cohort.
  • Black and Latin populations have been shown to have higher exposure to PM2.5 air pollution due to structural racism.
  • To assess the risks of prenatal air pollution exposure in minority populations, researchers recruited 1,261 mother-infant pairs from the University of Colorado.
  • The results found no evidence of an association between prenatal PM2.5 air pollution exposure and development of allergic disease or differences in air pollution exposure by race in a setting of low overall air pollution levels.

EQS-News: Marinomed Biotech AG with important progress for Carragelose in 2024

Retrieved on: 
Mittwoch, Februar 7, 2024
Internal medicine, Certification, Telecanthus, MDR, Trial of the century, Nose, Patient, Procter & Gamble, FDA, Canadian International Council, OTC, Allergic rhinitis, MDD, Medical device regulation, Medical device, Allergy

Marinomed has received patents covering the decongestant Carragelose/Sorbitol combination in Singapore, South Korea, and Brazil

Key Points: 
  • Marinomed has received patents covering the decongestant Carragelose/Sorbitol combination in Singapore, South Korea, and Brazil
    Korneuburg, Austria, 07 February 2024 – Marinomed Biotech AG (VSE:MARI) has enrolled the first patient in a clinical study to investigate the lubricating properties of Carragelose eye drops in patients diagnosed with mild to moderate dry eye disease.
  • Carragelose eye drops are planned to launch in Austria in 2024.
  • Next to the eye drops, also the launch of the allergen-blocking Carragelose nasal spray is planned for 2024.
  • We are happy that the Carragelose business is constantly making progress and we continue to maximize the value of this asset”, Andreas Grassauer, Marinomed’s CEO, mentions.